Magnetic Resonance Imaging for Imaging of Tumor Microenvironment of Metastasis in Patients with Operable Breast Cancer

Inclusion Criteria

• For pre-pilot phase (MRI sequence development): * Patients with a breast mass, with biopsy-proven histology of invasive breast carcinoma (any histologic type and estrogen receptor [ER], progesterone receptor [PR], HER2 status)
• For pilot phase cohort A: * Patients with a breast mass considered highly suspicious for invasive carcinoma by the radiologist (Breast Imaging Reporting and Data System [BIRADS] 5)
• For pilot phase cohort B: * Patients with a breast mass found to be invasive ductal carcinoma on core biopsy * The tumor should be considered operable by the breast surgeon * No preoperative therapy for the current breast cancer is planned (endocrine therapy, chemotherapy, or radiation)
• Tumor size/breast mass should be > 1 cm in largest diameter (radiologically)
• Multifocal disease is allowed, as long as patients meet all eligibility criteria
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Willingness to undergo a “research breast MRI”
• Patient must be able to undergo MRI with gadolinium enhancement * No history of untreatable claustrophobia * No presence of non MRI compatible metallic objects or metallic objects that, in the opinion of a radiologist, would make MRI a contraindication * No history of sickle cell disease * No contraindication to intravenous contrast administration * No known allergy-like reaction to gadolinium * No known or suspected renal impairment. Glomerular filtration rate (GFR) should be greater than 30 mL/min/1.73 m^2
• Weight less than or equal to the MRI table limit
• Ability to understand and willingness to sign a written informed consent

Exclusion Criteria

• Patients may not have had breast cancer or radiation therapy to the ipsilateral breast in the past
• No breast prosthetic implants (silicone or saline) are allowed
• Use of any investigational agent within 30 days of starting study
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study
• Patients must be non-pregnant and non-lactating. Patients must have a negative pregnancy test (urine or serum) within 7 days of registration date